Sen. Rand Paul (R-KY) has subpoenaed Dr. Anthony Fauci to appear before the Senate this July [3].
The move follows years of contention regarding the origins of COVID-19 and whether U.S. government funds supported risky research in China. The dispute centers on the definition of gain-of-function research, and the accountability of federal health agencies.
The current legal escalation stems from a confrontation during a March 10, 2021, Senate oversight hearing [1]. During that session, Paul said the National Institute of Allergy and Infectious Diseases funded dangerous coronavirus research at the Wuhan Institute of Virology [2].
Dr. Fauci, who had served 40 years in government at the time of the 2021 accusation [4], denied the allegations. "The NIH never funded gain-of-function research at the Wuhan Institute of Virology," Fauci said [1].
Paul rejected that explanation during the hearing, saying that the NIH funded dangerous coronavirus research in Wuhan [2]. The exchange highlighted a fundamental disagreement between the senator and the public health official over the nature of the grants provided to the lab.
Paul has continued to seek accountability for the alleged funding of risky research, arguing that such work contributed to the start of the pandemic. Fauci defended the agency's funding decisions and said that no gain-of-function work occurred at the facility [1].
On June 23, Paul confirmed the new legal action to bring the former director back to the Senate [3]. The subpoena aims to resolve the contradictions between the NIH's official position and the senator's claims regarding the Wuhan lab.
“"The NIH never funded gain-of-function research at the Wuhan Institute of Virology."”
This subpoena represents a continuation of the political and scientific conflict over the 'lab leak' theory. By forcing a return to testimony, the Senate seeks to determine if the NIH's definitions of research funding were used to obscure the nature of the work performed in Wuhan, which has significant implications for future biosafety regulations and U.S.-China diplomatic relations.
